In a randomized open-label study, new-onset AF in patients receiving ERT for more than 24 months was reported in two patients treated with agalsidase beta (n = 2/16; after 42 and 36 months) and one patient treated with agalsidase alfa (n = 1/18; after 30 months) (45). The gene discussed is GLA; the disease is atrial fibrillation.